Skip to content
AnalystLens

Zoetis Inc.ZTS

Sector
Healthcare
Industry
Pharmaceutical Preparations
Exchange
NYSE

Stock Price $ZTS

Latest filings

You are here#36 of 40 in Healthcare by market cap

Filing record · 2016–202610-K1110-Q338-K135

ZTS filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 135 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Leadership change8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Oct ’21Oct ’21
  4. Material agreement8-K · Dec ’25Dec ’25

01—Key figures

Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025

Revenue Trend

Year-over-year comparison from 10-K annual reports

  15. $9.47B
YoY changeLargest recent move+16.5%in FY21Latest +2.3%

Latest bar from 10-KFY2025Click a bar to open its SEC filing

View full history →
All ZTS Financial Metrics60 metrics

Income Statement13

Balance Sheet28

Cash Flow14

Per Share5

02—Overview

Zoetis Inc. Financial Overview 2021–2025

Updated Jul 10, 2026

Zoetis has engineered a decisive shift in its revenue base, with companion animal products swelling to a dominant 70%a of total sales by the end of FY2025. This structural transition away from livestock insulates the business from agricultural cyclicality and taps directly into inelastic consumer spending on pet healthcare. The underlying data outlines a highly profitable compounder leveraging aggressive price increases and massive share repurchases to drive earnings growth even as top-line volume normalizes.

Total revenue expanded steadily from $7.78 billion in FY2021 to $9.47 billionb in FY2025. While overall top-line growth decelerated to 2% in FY2025, Zoetis continues to extract more profit per dollar of sales through persistent price hikes and strategic divestitures like its medicated feed additive portfolio. These pricing levers pushed full-year net income up 8% to $2.67 billion in FY2025. The company channels this cash generation directly into equity reduction, authorizing a $6 billion buyback program in FY2024 and retiring millions of shares to concentrate ownership. At the close of FY2025, the market valued the resulting $53.5 billion enterprise at 20.9x earnings, with the stock trading at $125.82.

Recent Developments (Q4 2025 and Q1 2026)

Zoetis reported Q1 2026 revenue of $2.26 billionc, a 3% year-over-year increase supported by foreign exchange and price hikes. Net income contracted 1% to $601 million, while gross margins narrowed to 71.7% from 71.9% a year earlier. The company agreed to acquire Neogen's animal genomics business, scheduled to close in the second half of 2026. Segment performance diverged, with U.S. revenues falling 8% due to companion animal competition, while international sales surged 17%. Research and development expenses climbed 11% to $180 million.

Bulls view the genomics acquisition and a sustained $0.53d quarterly dividend as strong indicators of capital deployment, with shares trading at 14.5x earnings as of May 7, 2026. Bears warn that a 1% operational revenue decline and falling U.S. volumes expose vulnerabilities to rising market competition.

What to watch: closing of the Neogen animal genomics acquisition; recovery in U.S. companion animal product volumes.

03—Filings

Recent SEC Filings

  1. 8-KZoetis Inc. 8-K Report, Executive Changes (Oct 13, 2026)Zoetis Inc. (ZTS) announced a change to its Board of Directors with the appointment of Iris Knobloch, effective December 1, 2026. This appointment will increase the Board size from twelve to thirteen members. Ms. Knobloch will join the Corporate Governance Committee. The company stated that her appointment is not part of any pre-arranged agreements with third parties, and there have been no reportable related-party transactions. Ms. Knobloch will participate in the standard non-employee director compensation program and will be subject to the Company's standard indemnification agreement. This filing, primarily an Item 5.02 disclosure, signals an expansion of the board's oversight and governance expertise with the addition of Ms. Knobloch. Investors should note that this is a governance-related update and does not directly impact the company's financial performance or operational results as of the filing date. The press release attached as an exhibit provides formal confirmation of this board change.
  2. 8-KZoetis Inc. 8-K Report, Regulation FD Disclosure (Oct 8, 2026)Zoetis Inc. (ZTS) has announced a quarterly dividend payment of $0.53 per share for the fourth quarter of 2026. This declaration, made on October 8, 2026, signals continued commitment to returning capital to shareholders. The dividend is scheduled to be paid on December 1, 2026, to shareholders of record as of October 30, 2026. This information is being disclosed under Regulation FD and is accompanied by a press release. While this filing focuses solely on the dividend declaration and does not provide updates on financial performance or strategic initiatives, it represents a regular step in Zoetis' capital allocation strategy. Investors seeking to participate in this dividend should ensure their holdings are registered by the specified record date. The company has also included the standard cover page interactive data file in its filing.
  3. 8-KZoetis Inc. 8-K Report, Executive Changes (Aug 6, 2026)Zoetis Inc. (ZTS) has filed an 8-K report detailing significant executive leadership changes. The most prominent announcement is the appointment of James Saccaro as Executive Vice President, Chief Financial Officer, and Chief Operating Officer, effective August 17, 2026. Mr. Saccaro brings substantial experience from GE HealthCare and Baxter International and will be responsible for Zoetis's global finance functions and Global Manufacturing and Supply operations. Concurrently, the company announced the departure of Wetteny Joseph from his role as Executive Vice President and Chief Financial Officer. Mr. Joseph will transition to a non-executive advisory role through February 28, 2027, with his departure not related to any disagreements. These executive changes suggest a strategic shift in financial and operational leadership for Zoetis.
  4. 8-KZoetis Inc. 8-K Report, Financial Results (Aug 6, 2026)Zoetis Inc. (ZTS) has filed an 8-K report on August 6, 2026, announcing its financial results for the second quarter of 2026. The report also includes the company's updated guidance for the full fiscal year 2026. Investors should refer to the press release furnished as Exhibit 99.1 for detailed financial performance and forward-looking statements. While the filing itself primarily serves to attach the press release, the core information of interest to investors will be within that press release. This includes key metrics like revenue, earnings per share (EPS), profitability margins, and any commentary on factors influencing these results, such as product performance, market trends, and operational efficiencies. The updated full-year guidance is particularly crucial for assessing the company's future trajectory and potential returns.
  5. 8-KZoetis Inc. 8-K Report, Executive Changes (May 22, 2026)Zoetis Inc. (ZTS) filed an 8-K on May 22, 2026, reporting on its 2026 Annual Meeting of Shareholders held on May 20, 2026. The filing details the outcomes of five proposals voted on by shareholders, with a notable 90.13% of outstanding shares represented, indicating strong shareholder engagement. The meeting also marked the retirement of Ms. Louise M. Parent from the Board of Directors in accordance with the company's retirement policy. Key outcomes include the overwhelming re-election of all twelve director nominees, demonstrating continued confidence in the board's leadership. Shareholders also approved, on an advisory basis, the executive compensation program and affirmed the preference for an annual advisory vote on executive compensation. The appointment of KPMG LLP as the independent registered public accounting firm for fiscal year 2026 was ratified. However, a shareholder proposal to permit action by written consent was not approved.
View all 8-K filings →
View all filings (10-K, 10-Q, 8-K, proxy & more) →

04—See also

Related Companies

Annual revenue over each company’s last eight fiscal years, each strip on its own scale from zero.